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Abstract: To improve the in vivo resorption of an inject-
able calcium phosphate cement (CPC) for bone tissue engi-
neering purposes, in previous experiments macroporosity
was introduced by the in situ degradation of incorporated
gelatin microspheres. Gelatin microspheres are also suita-
ble carriers for osteoinductive drugs/growth factors,
where release occurs concomitantly with degradation of
the hydrogel. Introduction of these microspheres into CPC
can alter the release pattern of the cement, which usually
shows a marginal release of incorporated drugs. The goal
of this study was to determine the in vitro release charac-
teristics of gelatin microsphere CPC. For this, recombinant
human TGF-b1, bFGF, and BMP-2 were labeled with 125I
and loaded onto gelatin type A (porcine, pI 5 7.0–9.0)/
type B (bovine, pI 5 4.5–5.0) microspheres for a short
(instant) and longer (prolonged) time before mixing them
with the cement. Radioactivity of the resulting 5 or 10 wt %
gelatin microsphere CPC composites was monitored for 6
weeks when subjected to proteolytic medium. Drug-
loaded CPC was used as control. Results showed that
release pattern/efﬁciency of gelatin microsphere CPCs
and CPC controls was highly dependent on the type of
growth factor but unaffected by the amount of growth
factor. With gelatin microsphere CPC, release was also
dependent on the type of gelatin, total volume of incorpo-
rated microspheres, and loading method.  2008 Wiley
Periodicals, Inc. J Biomed Mater Res 91A: 614–622, 2009
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INTRODUCTION
Calcium phosphate cements (CPCs) are commonly
used as bone-ﬁlling materials in the ﬁeld of den-
tistry, orthopedic, and postoperative surgery. These
cements have proven be biocompatible and osteo-
conductive, and because of the in-situ setting abil-
ities, a perfect ﬁt with the site defect can be accom-
plished.1,2 One disadvantage is the high density and
slow degradability of the material, which makes it
less applicable for tissue engineering purposes.3
Therefore, in earlier studies by our group micro-
spheres made of poly(lactic-co-glycolic acid)
(PLGA)4–8 and gelatin9,10 were added to an apatite
cement. These microsphere CPCs exhibited good
injectability characteristics and setting properties.
During in vitro/in vivo degradation of the spheres,
porosity increased concomitantly, yielding a struc-
ture of spherical pores and a decrease in mechanical
strength. PLGA microspheres produced an acidic
environment due to the hydrolysis of the ester
groups.8 On the other hand, gelatin microspheres
degraded gradually by proteolysis and no additional
decrease in pH was observed.9 Drug release studies
with microsphere CPC were also performed as the
addition of osteoinductive drugs can improve bone
remodeling at the implant site.11,12 The drug was
incorporated or adsorbed onto the microspheres to
give a release pattern that differs from the usual dif-
fusion dependent release from CPCs.13,14 In vitro/
in vivo release data of bone morphogenic protein-2
(BMP-2) from PLGA microsphere CPC overall
showed a pattern that was characterized by a small
burst release, followed by a period of slow, sus-
tained release.4,5 Furthermore, by changing the mo-
lecular weight of the polymer release was tailored
within certain ranges as low molecular weight PLGA
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microsphere CPC showed a signiﬁcant higher release
after 4 weeks in vivo.5 In an in vitro release study
using gelatin microsphere CPC,10 microspheres were
loaded with bovine serum albumin (BSA) and
release from the microsphere CPC was monitored
for 9 weeks. Two loading methods were applied;
BSA was loaded onto the microspheres directly
before mixing (instant loading) or 24 h before mixing
(prolonged loading) to establish a strong electrostatic
bond between the basic gelatin (type A, pI 5 7.0–
9.0) and the acidic BSA (pI 5 5.0).15 Results showed
a release pattern without initial burst and a delayed
release after 3 days that decreased in time. Release
up to three weeks was signiﬁcantly higher with the
instant loaded scaffolds, whereas the prolonged
loaded scaffolds exhibited a more sustained release.
Structure analysis by sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) showed
peaks of intact BSA after 3, 7, and 17 days. Gelatin
microsphere CPC therefore seems to be a suitable
scaffold for drug delivery; however, growth factors
like BMP-2, transforming growth factor-b (TGF-b),
vascular endothelial growth factor (VEGF) and basic
ﬁbroblast growth factor (bFGF) can show a com-
pletely different release pattern than BSA.1 In addi-
tion, there exist two types of gelatin; type A (pI 5
7.0–9.0) and type B (pI 5 4.5–5.0) that because of
their opposite isoelectric point exhibit different elec-
trostatic interactions with various drugs/proteins.15
The goal of this study was to determine the
release characteristics of gelatin type A or type B
microsphere CPC by loading the scaffolds with vari-
ous types of growth factor (TGF-b, bFGF, and BMP-
2) and applying two loading mechanisms. Also, dif-
ferent amounts of growth factor were loaded onto
the gelatin microspheres to investigate whether
release from these composites is concentration de-
pendent. Release was measured by labeling the
growth factors with 125I after which radioactivity of
the loaded composites and release medium (phos-




Cell culture tested gelatin type A (GELA) (pI 5 7.0–9.0,
bloom 5 300) and gelatin type B (GELB) (pI 5 4.7–5.2,
bloom 5 225) (Sigma-Aldrich, St. Louis, USA) were used
for the fabrication of the microspheres. The CPC used is
commercially available under the product name Calcibon1
(Biomet Merck, Darmstadt, Germany) and consists of 61%
a-tricalcium phosphate (a-TCP), 26% Ca2HPO4, 10%
CaCO3 and 3% precipitated hydroxyapatite (pHA). Colla-
genase 1A (Sigma) was used as gelatin degrading enzyme.
Recombinant human transforming growth factor b1 (TGF-
b1, pI 5 9.5), basic ﬁbroblast growth factor (bFGF, pI 5
9.6), and bone morphogenic protein-2 (BMP-2, pI 5 8.5)
(R&D systems Europe Ltd., Abingdon, UK) were the
growth factors used in the release experiment.
Preparation of gelatin microspheres
Totally, 2.5 g of GELA or GELB was dissolved in 25 mL
ddH2O at an elevated temperature (30 min at 608C). The
resulting clear solution was added slowly (10-mL pipette)
to a 250-mL three-necked round bottom ﬂask containing
125 mL olive oil while stirring at 500 rpm (Teﬂon upper
stirrer). During stirring, the round bottom ﬂask was put in
an ice bath. After 30 min, 50 mL of chilled acetone (48C)
and glutaraldehyde (0.5 mL 5 6.25 mM) was added
slowly. The solution was stirred for another hour. Micro-
spheres were collected by ﬁltration (D3, Schott Duran,
Mainz, Germany) and washed several times with acetone
(1 L) to remove residual olive oil. Following this, micro-
Figure 1. Morphology microspheres by scanning electron microscopy; (A) GELA microspheres, (B) GELB microspheres
(original magniﬁcation 1003).
RELEASE FROM INJECTABLE CPCs CONTAINING GELATIN MICROSPHERES 615
Journal of Biomedical Materials Research Part A
spheres were stored in a drying chamber until further use.
Morphology of the microspheres was visualized by scan-
ning electron microscopy (SEM) (JEOL 6400-LINK AN
10000 at 10 kV) and is shown in Figure 1. Average size of
the microspheres is given in Table I and was determined
using digital image software (Leica Qwin1, Leica Micro-
systems AG, Wetzlar, Germany).
Radioiodination of growth factors
TGF-b1, bFGF and BMP-2 were labeled with 125I accord-
ing to the iodogen method.16 Brieﬂy, in a 500-lL eppen-
dorf tube coated with 50-lg iodogen 10 lL of 0.5M phos-
phate buffer saline (PBS) was added and adjusted to 100
lL with 50 mM PBS. Growth factor (8 lg) and 10–15 MBq
125I (Perkin-Elmer, Boston, MA) was added and incubated
at room temperature for 10 min. After that, 100 lL of satu-
rated Tyrosine solution in PBS was added and labeling ef-
ﬁciency of the reaction was 36%, 13%, and 43% for TGF-
b1, bFGF, and BMP-2, respectively. To remove the non-
bound I125 activity, the reaction mixture was eluted with
0.1% BSA in PBS on a prerinsed disposable Sephadex
G25M column (PD-10; Pharmacia, Uppsala, Sweden). The
radiochemical purity of the 125I-labeled growth factors was
determined by instant thin layer chromatography (ITLC)
on Gelman ITLC-SG strips (Gelman Laboratories, Ann
Arbor, MI) with 0.1M citrate, pH 5.0 as a mobile phase.
The radiochemical purity of the growth factors is pre-
sented in Table II.
Preparation of gelatin microsphere/CPC composites
For the release study, 10 wt % gelatin type A micro-
sphere CPCs (GELA CPCs) and 5 wt % gelatin type B
microsphere CPCs (GELB CPCs) were prepared as
described in previous studies.9,10 The weight % of micro-
spheres inside the cement corresponds to the maximum
amount of microspheres that can be incorporated to still
obtain a composite with manageable handling properties.10
TGF-b1, bFGF, and BMP-2 was loaded onto the composites
by two loading methods where growth factor was mixed
with the cement directly after loading them to the micro-
spheres (instant loading), or following a period of swelling
before cement was added (prolonged loading). Brieﬂy,
growth factor loaded 5/10 wt % gelatin microsphere CPCs
were made by adding a growth factor solution in PBS
(300/560 lL) to 50/100 mg of dry gelatin microspheres
inside a BSA coated 2-mL syringe. With instant loading,
after 15 s of vigorous stirring using a Silamat1 (Vivadent,
Schaan, LIE) mixing apparatus, 950/900 mg CPC was
added and the constituents were stirred again for 15 s or
until an equal distribution of spheres inside the cement
was obtained. With the prolonged loaded composites, the
gelatin microspheres were allowed to swell for 24 h at 48C
before they were mixed with the cement. Following both
procedures, 280 lL of 1% Na2HPO4 was added and after
15 s of stirring, the resulting paste was injected into Teﬂon
moulds (cylindrical, d 5 4.5 mm, h 5 9.0 mm). Samples
were hardened at room temperature overnight. SEM-
micrographs of the gelatin microsphere CPCs are given in
Figure 2. Growth factor-loaded samples without micro-
spheres (CPC) were used as control and prepared by add-
ing a growth factor solution to preset cement samples
(adsorbed). Calculated amount of growth factor per sam-
ple is 50 ng. Furthermore, drug entrapment efﬁciency was
TABLE II
Radiochemical Purity 125I-Labeled Growth Factors
TGF-b1 bFGF BMP-2
Radiochemical purity 95.6% 83.9% 97.8%
TABLE I
Average Size Gelatin Microspheres (n 5 200)
Average Size (lm)
Dry Swollen
GELA microspheres 15.5 6 13.8 37.4 6 31.1
GELB microspheres 8.4 6 7.6 20.7 6 14.6
Figure 2. Morphology gelatin microsphere CPCs; (A) 10% GELA CPC, (B) 5% GELB CPC (original magniﬁcation 1003).
616 HABRAKEN ET AL.
Journal of Biomedical Materials Research Part A
determined by measuring the g-irradiation of the preset
samples after which it was divided by the g-irradiation of
the corresponding calculated amount of labeled growth
factor.
With BMP-2 some supplementary studies were per-
formed. To investigate whether growth factor release is
concentration dependent, different amounts of BMP-2
were incorporated into the cement. Next to 50 ng of 125I-
labbeled BMP-2 per scaffold, samples were loaded with
500 ng and 5 lg of BMP-2 applying hot/cold ratios of 1/
10 and 1/100. Furthermore to investigate the effect on
drug release of the total amount/volume of incorporated
microspheres, with BMP-2 also a 5 wt % GELA CPC was
formulated. Volume % of gelatin microspheres inside the 5
and 10 wt % GELA CPC10 and 5 wt % GELB CPC is pre-
sented in Table III. Finally, in addition to the adsorbed
CPC controls, CPC samples were prepared where BMP-2
was dissolved into the liquid hardener (1% Na2HPO4) dur-
ing cement preparation (incorporated). In Table IV a
scheme of the different parameters used during the experi-
ment is presented.
Release study
Samples were placed in 3 mL PBS containing 373 ng/
mL collagenase 1A17 inside 10 mL polypropylene tubes.
Tubes were put in a water bath containing a rotating plate
(70 rpm) at 378C. Medium was renewed every 3–4 days.
At the same time, g-irradiation of the sample/medium
was measured for a total of 6 weeks. Samples were taken
and measured in triplicate (n 5 3).
Statistical analysis
Data were presented as mean 6 standard deviation. Sig-
niﬁcant differences were determined using analysis of var-
iance (ANOVA). Results were considered signiﬁcant if p <
0.05. Calculations were performed using GraphPad
Instat1.
RESULTS
The drug entrapment efﬁciencies of the samples
are given in Table V. For all types of gelatin micro-
sphere CPC, drug entrapment efﬁciencies were
around 70–75%. Differences in entrapment efﬁciency
between instant and prolonged loaded scaffolds
were observed, though no clear trend was observed.
CPC controls where the BSA was adsorbed exhibited
higher entrapment efﬁciencies (82–94%) than the gel-
atin microsphere CPC, though the incorporated CPC
showed an efﬁciency of only 51%.
The release pattern for the CPC is given in Figure
3. Overall, CPC where the drug was adsorbed onto
the surface exhibited a release pattern consisting of
an initial burst, followed by a sustained release that
was slowly diminishing in time. The release pattern
of both BMP-2 and bFGF was similar, whereas the
TGF-b1 showed a signiﬁcant lower initial burst and
sustained release. In contrast to the BMP-2 adsorbed
CPC, release from the BMP-2 incorporated cement
TABLE III
Vol % of Microspheres Inside Gelatin Microsphere CPC
Formulation Volume % of Microspheres
5% GELA CPC 48.7 6 1.8%
10% GELA CPC 57.5 6 1.4%
5% GELB CPC 48.4 6 1.8%
TABLE IV










Instant 50 50 50 500 5000
Prolonged 50 50 50 500 5000
5% GEL B
CPC
Instant 50 50 50 500 5000
Prolonged 50 50 50 500 5000
5% GELA
CPC
Instant – – 50 – –
Prolonged – – 50 – –
CPC
(control)
Adsorbed 50 50 50 500 5000
Incorporated – – 50 – –
TABLE V
Entrapment Efﬁciency Gelatin Microsphere CPC and CPC as Percentage of Calculated Amount of Growth Factor




CPC (adsorbed) 81.7 6 3.4 82.3 6 3.1 93.7 6 4.2 90.7 6 4.7 88.5 6 2.9
10% GelA CPC instant 74.8 6 1.8 75.7 6 2.6 77.7 6 2.3 78.8 6 1.5 75.7 6 1.9
10% GelA CPC prolonged 66.8 6 1.7 76.1 6 0.5 71.0 6 2.0 72.1 6 1.3 68.3 6 1.6
5% GelB CPC instant 72.4 6 2.8 69.4 6 0.4 77.8 6 2.4 81.0 6 4.3 73.1 6 4.4
5% GelB CPC prolonged 68.5 6 0.2 68.8 6 1.6 71.4 6 0.9 71.1 6 1.0 70.0 6 1.3
CPC (incorporated) – – 50.9 6 2.3 – –
5% GelA CPC instant – – 69.8 6 1.5 – –
5% GelA CPC prolonged – – 75.8 6 1.8 – –
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did not show an initial burst. Furthermore, sustained
release was comparable to the BMP-2 adsorbed
cement though release efﬁciency (Table VI), due to
the initial burst, was signiﬁcantly lower (p < 0.001).
Similar to the CPC samples, both 10% GELA CPCs
(Fig. 4) and 5% GELB CPCs (Fig. 5) exhibited a pat-
tern consisting of a (small) initial burst followed by
sustained release of the growth factor. Also here,
release was dependent on the type of growth factor,
where bFGF exhibited a higher burst release than
BMP-2 or TGF-b1. Sustained release and release efﬁ-
ciency (Table VI) was in the following order; bFGF
> BMP-2  TGF-b1. The 10% GELA CPC also
showed a signiﬁcant higher sustained release from
the prolonged loaded scaffolds when compared to
the instant loaded scaffolds for all growth factors.
With TGF-b1 the prolonged loaded scaffolds experi-
enced a 33% higher release after 6 weeks, whereas
with bFGF and BMP-2 this was 8% and 13%. The 5%
GELB CPC did not show such a trend, as with bFGF
the instant loaded scaffolds showed a signiﬁcant
higher release (p < 0.01), and differences between
instant and prolonged loaded scaffolds with BMP-2
and TGF-b1 were small.
In Figure 6 the BMP-2 release from all formula-
tions is depicted. It was observed that sustained
release from the 5% GELA CPC was signiﬁcantly
lower (p < 0.001) than the 10% GELA CPC, 5%
GELB CPC and CPC controls. Furthermore, sus-
tained release from the incorporated CPC was iden-
tical to the 5% GELB CPC and instant loaded 10%
GELA CPC, though slower than the prolonged
loaded 10% GELA CPC.
Figure 7 shows the absolute release from the BMP-
2 loaded composites. The release patterns at the dif-
ferent BMP-2 concentrations were identical for all
formulations and exhibited respectively a 10/100
fold increase in burst or sustained release and abso-
lute release after 6 weeks (Table VI) when implants
were loaded with a 10/100-fold higher amount of
BMP-2.
DISCUSSION
In this study, growth factor release from injectable
CPCs with incorporated gelatin microspheres was
investigated. For this purpose, TGF-b1, bFGF, or
BMP-2 was added to the gelatin microspheres before
they were mixed with the cement using two loading
methods. Furthermore, scaffolds were prepared
using either type A or type B gelatin microspheres.
In addition, for BMP-2 the effect of growth factor
concentration and amount of incorporated micro-
spheres on the release pattern was investigated.
Samples without gelatin microspheres (CPC) were
used as control where the growth factor was
adsorbed onto the scaffolds or added to the liquid
hardener (BMP-2).
Results showed that the drug entrapment efﬁ-
ciency of the CPC controls was dependent on the
loading method as the incorporated CPC sample
Figure 3. Growth factor release from CPC, *** 5 p < 0.001.
TABLE VI
Release Efﬁciency After 6 Weeks of Gelatin Microsphere CPC and CPC as Percentage of Actual Loaded protein




CPC (adsorbed) 33.5 6 1.4 63.9 6 4.4 62.5 6 5.4 56.2 6 2.8 57.4 6 2.3
10% GelA CPC instant 13.3 6 0.3 50.5 6 1.2 28.8 6 0.3 30.5 6 1.0 29.2 6 0.5
10% GelA CPC prolonged 17.8 6 0.5 54.3 6 1.4 32.5 6 1.4 32.0 6 0.8 34.2 6 1.4
5% GelB CPC instant 13.8 6 0.2 53.7 6 0.4 27.1 6 0.3 28.0 6 1.0 28.3 6 0.6
5% GelB CPC prolonged 14.4 6 0.4 50.7 6 1.0 28.1 6 0.4 28.0 6 0.6 28.3 6 0.2
CPC (incorporated) – – 28.3 6 1.0 – –
5% GelA CPC instant – – 20.7 6 0.3 – –
5% GelA CPC prolonged – – 18.6 6 0.3 – –
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clearly exhibited a signiﬁcant lower efﬁciency than
the adsorbed CPC samples. For the incorporated
CPC sample, losses occurred when drug adsorbed to
the syringe during mixing or when drug was
absorbed to the Teﬂon mould during cement hard-
ening. Entrapment efﬁciency of the gelatin micro-
sphere composites was intermediate. This indicates
that the (electrostatic) interaction between the drug
and microspheres was strong enough to retain drug
inside the spheres during mixing; however, part of
the growth factor will be dispersed into the sur-
rounding cement.15
With most formulations an initial burst release of
the growth factor was observed. With the growth
factor-adsorbed CPC most of the drug was located
at the outside of the sample, which explains the high
burst release.13,14 The CPC with incorporated BMP-2
did not show a burst release as the growth factor in
this sample was dispersed more evenly through the
cement, which is known for its protein-binding
capacity.13,14,18 Occasionally, with the gelatin micro-
sphere CPCs a substantial burst release was
obtained. Although the BMP-2 and TGF-b1 loaded
composites showed a burst release of 5–7%, with
bFGF a burst release of 16–18% was observed. This
burst release is probably due to the suboptimal
radiochemical purity of I125 labeled bFGF, which
was 84%. The radioactive preparation used in this
experiment therefore contained 16% free Iodine-125
that is expected to exhibit a fast release from the
scaffolds. Regarding this radiochemical purity, burst
release from gelatin microsphere CPC was low. As
gelatin scaffolds/microspheres often show a high
burst release,15,17,19 the low burst observed here is a
result of protein binding to the cement after release
from the microspheres.
Figure 4. Growth factor release from 10% GELA CPC,
* 5 p < 0.05, *** 5 p < 0.001.
Figure 5. Growth factor release from 5% GELB CPC,
* 5 p < 0.05, ** 5 p < 0.01.
Figure 6. BMP-2 release from gelatin microsphere CPC and CPC.
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Following the burst release, with each growth fac-
tor a sustained release was observed. With the CPC
controls, this sustained release is probably due to
diffusion of drug through the cement20,21 as the CPC
does not show signs of degradation or dissolution8–10.
Figure 8 shows that BMP-2 release from the incorpo-
rated CPC is proportional to the square root of time,
which is typical for a diffusion dependent release.
Prolonged loaded 10% GELA CPC, however, shows
a more linear sustained release. With the gelatin
microsphere CPCs drug release can also be the result
of the proteolytic degradation of microspheres. Sup-
posedly degradation of gelatin microspheres inside
the CPC is a gradual process from the outside of the
implant to the inner part,10 though in these samples
also an initial burst of free gelatin chains was
observed. According to literature,15 electrostatically
bonded growth factor releases concomitantly with
release of gelatin degradation products. The observa-
tion that the release from the 10% GELA CPC is
more rapid than from the 5% GELA CPC indicates
that a similar mechanism indeed occurs. Further-
more as the used collagenase speciﬁcally degrades
collagen or gelatin,22 no proteolytic degradation of
the growth factor is expected.
In most cases the magnitude of the sustained
release from the gelatin microsphere CPC was com-
parable to the CPC samples, whereas it was signiﬁ-
cantly lower with 5% GELA CPC. This can be due to
the fact that proteolytic gelatin degradation does not
occur in a high extent for the 5% GELA CPC and
most of the growth factor is retained in the gelatin
microspheres. In previous degradation studies9,10 it
was concluded that due to the low interconnectivity
of the microspheres inside a 5% gelatin microsphere
CPC, the enzyme did not penetrate the composite as
it experienced physical interactions with the sur-
rounding cement. The release that is observed from
the 5% GELA CPC is mostly due to diffusion from
the cement, which is higher with the CPC controls.
Figure 6 also shows that BMP-2 release from the 5%
GELB CPC is signiﬁcantly higher than release from
the 5% GELA CPC, whereas the vol % of micro-
spheres inside the composite is similar (Table III).
This can be explained by a better distribution of the
GELB microspheres into the cement, which are
smaller in size than the GELA microspheres, leading
to a higher interconnectivity and improved micro-
sphere degradation. Also, the lower isoelectric point
of gelatin type B can have caused the higher sus-
tained release from the GELB CPC, as the used
Figure 7. Cumulative BMP-2 release from 10% GELA CPC, 5% GELB CPC and CPC with different amount of incorpo-
rated BMP-2 (13 5 50 ng, 103 5 500 ng, 1003 5 5 lg).
Figure 8. BMP-2 release curves from BMP-2 incorporated
CPC and 10% GELA CPC with additional trend lines.
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growth factors all have an isoelectric point of 8.5–9.5.
The electrostatic interactions with the acidic GELB
microspheres (pI 5 4.5–5.0) will be stronger than
with the GELA microspheres (pI 5 7.0–9.0), leading
to smaller losses to the surrounding cement during
composite preparation. However, next to electrostatic
interactions, physical entanglements also play a role
in drug loading. Similar to the GELA CPC, an
increase in the percent of microspheres inside the
GELB CPC is supposed to improve drug release
from these composites. However, like food-grade
gelatin microspheres in a previous study,9 with
GELB microspheres the addition of more than 5 wt %
of microspheres renders a composite with insufﬁcient
setting properties.
Apart from the implant material, the release test
showed large differences in the sustained release of
the various growth factors, that is showing a fast
release of bFGF and a much slower release of TGF-
b1. In agreement with other studies with cement or
gelatin as scaffold material,15,19,23 release in this
study was highly dependent on the type of growth
factor. Intrinsic and physical parameters like the iso-
electric point,15,19 hydration,24 and size of the drug
play an important role in drug release; however,
these parameters do not always have the same effect
on the release pattern/efﬁciency. Charge distribution
and chain conformation of the drug are markedly
inﬂuenced by environmental conditions like buffer
capacity (pH) and consistency of the medium.15,24
Also the state of the cement surface changes when
these environmental conditions alter, resulting in a
more positively/negatively charged substrate.25 It is
therefore not always straightforward to predict
release from these CPCs, despite the similarities
between the drugs.
In the previous BSA release study10 it was shown
that the loading method also can be used to tailor
release from the 10% GELA CPCs. In accordance to
this study, current results indeed showed that
absorption of the growth factor for a longer period
onto the microspheres (prolonged loading), led to a
higher sustained release with these composites. The
explanation for this phenomenon is a higher release
from the gelatin microspheres during proteolytic
degradation as result of stronger electrostatic interac-
tions between the gelatin and growth factor, and less
losses to the surrounding cement. GELA CPC (5%)
and GELB CPC (5%) do not, or to a lesser extent,
show this feature.As discussed earlier, proteolytic
degradation did not occur in a high extent for the
5% GELA CPC and therefore it is not surprising that
with this formulation the prolonged loaded samples
did not show a higher sustained release than the
instant loaded samples. Furthermore, as electrostatic
interactions between the gelatin and growth factors
are expected to be stronger with GELB microspheres,
these interactions already could be optimal using
instant loading.
Another feature that was observed in the BSA
release study10 was a substantial higher release from
the instant loaded scaffolds within the ﬁrst weeks
due to weaker electrostatic interactions between the
drug and gelatin. In our study, in most cases growth
factor release up to 3 weeks was similar for both
instant and prolonged loaded samples. With bFGF
loaded 5% GELB CPC there was a 10% higher
release from the instant loaded scaffolds within the
ﬁrst weeks, though with BSA a 100% higher release
was obtained. Comparison of both studies, the type
of drug (BSA/growth factor), substrate medium (de-
mineralized water/PBS), and drug concentration (1.5
mg/50–5000 ng) used during the release experiment
all could have inﬂuenced drug release. The use of
demineralized water in the BSA release study also
resulted in a strong decrease of the pH. An increase
in drug concentration can inﬂuence release proper-
ties as protein-binding sites are saturable.26 Increas-
ing BMP-2 loading from 50 ng to 5 lg in this study
did not lead to a different release pattern or efﬁ-
ciency, but a proportional increase in absolute
release. Within this range, sustained release from the
gelatin microsphere CPCs and CPC controls there-
fore can be tuned to a certain therapeutic amount
per week.
CONCLUSION
Gelatin microsphere/CPC composites can be
applied for the sustained release of growth factors.
The composites showed release efﬁciencies of 14–
55% and release patterns consisting of a small initial
burst followed by a sustained release up to 6 weeks.
CPC controls showed a higher burst release as well
as release efﬁciency when drug was adsorbed at the
outside of the sample, but a comparable pattern
and release efﬁciency when drug was incorporated
during cement preparation. Sustained release from
the gelatin microsphere CPCs was highly depend-
ent on the type of growth factor and was also de-
pendent on the total volume of microspheres and
type of gelatin. Also the loading mechanism was
important, as instant loaded 10% GELA CPC
showed a signiﬁcant higher sustained release than
prolonged loaded composites. Furthermore, release
patterns/efﬁciencies from the gelatin microsphere
composites and CPC controls did not differ signiﬁ-
cantly when BMP-2 concentration was increased
with a factor of 10–100.
Scanning electron microscopy was performed at the Mi-
croscopic Imaging Centre (MIC) of the Nijmegen Centre
for Molecular Life Sciences (NCMLS), the Netherlands.
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